6533b7cffe1ef96bd1257c98

RESEARCH PRODUCT

Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-γ inhibition.

Nadezda ApostolovaJuan V. EspluguesAna Blas-garcia

subject

Mitochondrial DNAMitochondrial DiseasesNucleic Acid Synthesis InhibitorDNA polymeraseAnti-HIV Agentsmedicine.medical_treatmentDNA-Directed DNA PolymeraseMitochondrionPharmacologyToxicologyAntiretroviral Therapy Highly ActivemedicineAnimalsHumansNucleic Acid Synthesis InhibitorsPharmacologyProteasebiologyvirus diseasesmedicine.diseaseReverse transcriptaseDNA Polymerase gammaMitochondriaMitochondrial toxicityToxicitybiology.proteinReverse Transcriptase Inhibitors

description

The combined pharmacological approach to the treatment of HIV infection, known as highly active antiretroviral therapy (HAART), has dramatically reduced AIDS-related morbidity and mortality. However, its use has been associated with serious adverse reactions, of which those resulting from mitochondrial dysfunction are particularly widespread. Nucleos(t)ide-reverse transcriptase inhibitors (NRTIs) have long been considered the main source of HAART-related mitochondrial toxicity due to their ability to inhibit Pol-γ, the DNA polymerase responsible for the synthesis of mitochondrial DNA. Nevertheless, accumulating evidence points to a more complex relationship between these organelles and NRTIs. Also, alternative pathways by which other groups of anti-HIV drugs (non-nucleoside reverse transcriptase inhibitors and protease inhibitors) interfere with mitochondria have been suggested, although their implications, both pharmacological and clinical, are open to debate. This review aims to provide a comprehensive overview of the mechanisms and factors which influence the mitochondrial involvement in the toxicity of all three major classes of anti-HIV drugs.

10.1016/j.tips.2011.07.007https://pubmed.ncbi.nlm.nih.gov/21899897